MedTrace Logo

Artificial Intelligence-based Parkinson's Disease Risk Assessment (AI-PRA) Study

NCT07706829 · Status: NOT_YET_RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2026-07-20

No results posted yet for this study

Summary

The study aims to provide initial proof-of-concept validation data of an artificial intelligence-based model to estimate individual Parkinson's disease risk using demographic, clinical, genetic information and digital biomarker data collected via a smartwatch and a mobile application.

Conditions

  • Parkinson Disease (PD)
  • REM Sleep Behavior Disorder (iRBD)
  • Neurogenic Orthostatic Hypotension
  • Hyposmia

Interventions

DEVICE

Smartwatch and phone app

Wearing a smartwatch and using a mobile phone application for 6 months in order to provide digital biomarker data and additional self reported clinical information.

Sponsors & Collaborators

  • Hospital Ruber Internacional

    collaborator OTHER

  • University Hospital, Toulouse

    collaborator OTHER

  • Aristotle University Of Thessaloniki

    collaborator OTHER

  • Queen Mary University of London

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-01
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • France
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07706829 on ClinicalTrials.gov